Vaccibody As Analysis
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Vaccibody As is fairly valued with Real Value of 2.26 and Hype Value of 2.23. The main objective of Vaccibody delisted stock analysis is to determine its intrinsic value, which is an estimate of what Vaccibody As is worth, separate from its market price. There are two main types of Vaccibody's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Vaccibody's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Vaccibody's stock to identify patterns and trends that may indicate its future price movements.
The Vaccibody stock is traded in Norway on Oslo Stock Exchange, with the market opening at 09:00:00 and closing at 16:20:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Norway. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Vaccibody's ongoing operational relationships across important fundamental and technical indicators.
Vaccibody |
Vaccibody Stock Analysis Notes
About 50.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.36. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vaccibody As recorded a loss per share of 1.59. The entity had not issued any dividends in recent years. Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more information please call William MBA at 44 1865 818 808 or visit https://www.vaccitech.co.uk.Vaccibody As Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vaccibody's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vaccibody As or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Vaccibody As is not yet fully synchronised with the market data | |
| Vaccibody As has a very high chance of going through financial distress in the upcoming years | |
| Vaccibody As currently holds about 192.33 M in cash with (14.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.17, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Vaccibody As Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vaccibody previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of November 2023 Upcoming Quarterly Report | View | |
| 22nd of March 2024 Next Financial Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 22nd of March 2024 Next Fiscal Year End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Vaccibody Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 192.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vaccibody's market, we take the total number of its shares issued and multiply it by Vaccibody's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Vaccibody As Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaccibody insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaccibody's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaccibody insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scheeren Joseph over a year ago Purchase by Scheeren Joseph of 10000 shares of Vaccitech PLC | ||
Wright Robin over a year ago Purchase by Wright Robin of 13750 shares of Vaccitech PLC | ||
Enright William over a year ago Sale by Enright William of 15000 shares of Vaccitech PLC | ||
Pelletier Nadege over a year ago Acquisition by Pelletier Nadege of 485000 shares of Vaccitech PLC subject to Rule 16b-3 | ||
Chris Ellis over a year ago Acquisition by Chris Ellis of 105000 shares of Vaccitech PLC subject to Rule 16b-3 | ||
Hammacher Alex over a year ago Acquisition by Hammacher Alex of 18604 shares of Vaccitech PLC subject to Rule 16b-3 |
Vaccibody Outstanding Bonds
Vaccibody issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaccibody As uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaccibody bonds can be classified according to their maturity, which is the date when Vaccibody As has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Vaccibody Predictive Daily Indicators
Vaccibody intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vaccibody stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Vaccibody Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Vaccibody prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vaccibody shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Vaccibody. By using and applying Vaccibody Stock analysis, traders can create a robust methodology for identifying Vaccibody entry and exit points for their positions.
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Vaccibody to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |